June 15, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ACP has published living clinical guidance to help physicians select medications for patients with overweight or obesity. Unhealthy weight remains a significant public health issue globally, with 68.5% of American adults and 59% of adults worldwide having overweight or obesity, according to Amir Qaseem, MD, PhD, MHA, MGIN, MRCP, FACP, ACP chief science officer and senior vice president of
June 15, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Incretin-based medications lower high-sensitivity C-reactive protein levels among adults with a range of cardiometabolic…

The AMA passed a resolution to increase access to anti-obesity medications at its annual House of Delegates meeting.The…

AGA’s recent white paper provides a framework to navigate the latest innovations in obesity care, including GLP-1 receptor…

Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy.The…

WASHINGTON — GLP-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists are not likely to…

Once-weekly injectable semaglutide 2.4 mg was linked to reductions in body weight and improvements in multiple cardiometabolic…